O-1602 |
Neurogenesis, neuronal formation |
microglial activation |
|
[68] |
IL-4, IL-10 |
|
Inflammasome activation, IL-1β, IL-6, TNFα |
[70] |
|
|
Anxiety-like behavior |
[42, 70] |
|
|
Depression-like behavior |
[41, 70] |
|
PGE2
|
|
[71] |
hippocampal & frontal GPR55 expression |
|
RhoA/ROCK2, IL-1β, TNFα, neuronal apoptosis, cognitive impairment |
[84] |
|
|
IL-1β, IL-6, TNFα, Acetylcholinesterase (AChE) activity, microglial activation |
[85] |
|
|
NF-κB signaling, IL-1β, IL-6, TNFα, GPR55 downregulation, neuronal apoptosis, cognitive impairment |
[86] |
LPI |
|
IL-1β, IL-2, IL-10, IL-12, IFNγ |
IL-6, TNFα |
[69] |
CID1792197 |
Cell growth |
Cell growth in CB1-GPR55 heterodimer cells |
|
[88] |
Antagonists |
ML 193 |
Anxiety-like behavior |
|
|
[42] |
|
|
PGE2
|
[71] |
CID16020046 |
|
|
IL-6, COX-2 |
[72] |
Coumarin derivates |
|
|
PGE2, COX-2, (IL-6) |
[60, 71, 79] |
CBD |
Antipsychotic effects |
|
|
[81] |